Conditions
Fatty Liver Disease: MASLD and MASH
Fatty liver disease is metabolic disease showing up in the liver. It is usually silent, it is detected on labs or imaging, and the stage of scarring matters far more than the amount of fat.
Why fat collects in the liver
The liver is the body's metabolic hub. When insulin signaling is impaired, the liver both takes in more fat and produces more of it. Over time that fat accumulates inside liver cells.
The current names, MASLD and MASH, replaced older terminology to reflect what the disease actually is: liver disease driven by metabolic dysfunction. MASLD describes fat in the liver. MASH adds inflammation and cell injury, which is what leads to scarring.
From fat to inflammation to scarring
Fat alone is relatively quiet. Inflammation is the turning point. Injured liver cells trigger repair, and repeated repair lays down fibrous tissue. Enough fibrosis over enough years becomes cirrhosis.
The progression is slow and silent, and it is not inevitable. Fibrosis stage is the single strongest predictor of long term outcome, which is why staging matters more than the presence of fat by itself.
How the liver is assessed
Liver enzymes start the conversation but do not settle it. Enzymes can be normal even with significant disease. Other causes are ruled out first, including viral hepatitis, alcohol related injury, medication effects, and autoimmune disease.
Non invasive scoring built from routine labs estimates fibrosis risk. Elastography, an ultrasound based measure of liver stiffness, refines it. Biopsy is reserved for cases where the diagnosis or stage remains unclear. Hepatology manages this pathway.
- Liver enzyme panel and platelet count
- Testing to exclude viral, autoimmune, and alcohol related causes
- Non invasive fibrosis scoring
- Elastography for liver stiffness
- Liver biopsy in selected unclear cases
What changes the course
Treatment aims at the metabolic driver. Improving insulin sensitivity reduces liver fat. Reducing liver fat reduces inflammation. Reducing inflammation slows or stops fibrosis.
Nutrition change, alcohol reduction, treatment of diabetes and lipids, and medication where indicated all contribute. Metabolic procedures have been studied specifically for their effect on liver fat and inflammation, and hepatology and surgery frequently plan together in advanced cases.
Where a surgical evaluation fits
A surgical opinion is reasonable when fatty liver disease coexists with type 2 diabetes or other metabolic conditions, when fibrosis staging shows progression, or when medical management has not moved the picture. Liver status also affects operative planning, so it is assessed before any procedure.
This page is educational information, not medical advice. What is right for you is decided in consultation, after a review of your history, your symptoms, and your testing.
Common questions
- Is fatty liver disease serious if I feel fine?
- It can be. The disease is usually silent until late. Feeling well does not tell you the fibrosis stage, which is why staging is done rather than assumed.
- Can liver fat go away?
- Liver fat frequently decreases when the metabolic driver is treated. Early fibrosis can improve as well. Advanced scarring is far less reversible, which is the argument for acting early.
- Do I need a liver biopsy?
- Most people do not. Blood based scoring and elastography answer the question in the majority of cases. Biopsy is reserved for genuinely unclear situations.
- Should I stop drinking alcohol?
- Alcohol adds a second source of liver injury on top of the metabolic one. Reducing or stopping is commonly advised, and your hepatologist or primary care physician will individualize that.
Related conditions and services
Next step
Bring your liver enzymes and any imaging reports. Staging guides everything else.
Request a consultationLast reviewed